Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AbbVie's Upadacitinib Safety Appears Improved In Largest, Longest RA Study

Executive Summary

AbbVie's JAK1 inhibitor upadacitinib bested the company's blockbuster Humira in the largest and longest trial to date – on both efficacy and safety – perhaps alleviating concerns about cardiovascular events.

You may also be interested in...



First Phase III Results Keep Pfizer's Abrocitinib Among JAK Leaders In Atopic Dermatitis

Pfizer follows Lilly as the second company to report positive top-line Phase III results in AD for a JAK inhibitor. Safety is a key concern for the class, but Pfizer did not provide any details about abrocitinib's side effects.

While You Were Out: News In Brief

Updates from the holiday season include a Phase III failure for Pfizer's MRSA vaccine, AbbVie's submission of upadacitinib for rheumatoid arthritis and several year-end US approvals and FDA actions. 

Sierra Believes It Can Do Better Than Gilead With JAK Inhibitor Momelotinib

With many on the executive team who worked on the drug previously, Sierra thinks the stalled Phase III compound could be differentiated from Jakafi and others in the myelofibrosis space based on anemia benefit.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC100720

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel